BDX · News · 20260809N
Revenue Performance and Mix
BECTON DICKINSON & CO · 2026-08-09 · Importance 13 · Surprise 6 · In source text
Becton Dickinson reported fiscal Q3 2026 sales of US$4,983 million. The quarter exceeded market expectations, although the digest does not provide year-over-year or sequential revenue comparisons. Biologic drug delivery was identified as a key source of momentum during the quarter.
Key facts
- Q3 fiscal 2026 sales: US$4,983 million. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Q3 fiscal 2026 sales: US$4,983 million. |